Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 13/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040846 | 0.93 | CACNA1B (0.73) | CACNA1BKMT2AMEN1 | |
| SCHEMBL7041779 | 0.92 | CACNA1B (0.72) | CACNA1BOPRD1KMT2A | |
| SCHEMBL7038932 | 0.85 | CACNA1B (0.72) | CACNA1BKMT2AMEN1 | |
| SCHEMBL7043569 | 0.83 | CACNA1B (0.72) | CACNA1BKMT2AMEN1 | |
| SCHEMBL7043641 | 0.83 | CACNA1B (0.75) | CACNA1BKMT2A | |
| SCHEMBL7037028 | 0.83 | CACNA1B (0.74) | CACNA1BKMT2A | |
| SCHEMBL7352079 | 0.83 | CACNA1B (0.62) | CACNA1BOPRD1KMT2AMEN1 | |
| SCHEMBL7037601 | 0.82 | CACNA1B (0.68) | CACNA1BOPRD1 | |
| SCHEMBL7040197 | 0.82 | CACNA1B (0.59) | CACNA1BOPRD1KMT2A | |
| SCHEMBL7040157 | 0.82 | CACNA1B (0.59) | CACNA1BOPRD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | claimed |
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885OPRD1 1767/4885KMT2A 4017/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885OPRD1 1767/4885KMT2A 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.